论文部分内容阅读
目的：探讨应用米托蒽醌+阿糖胞苷+足叶乙甙(MAE)方案治疗CD7+急性髓性白血病(CD7+AML)的有效性。方法：采用MAE方案联合化疗治疗经细胞形态学、细胞化学及细胞免疫学分型诊断为CD7+AML12例，并监测化疗后骨髓像变化及化疗相关毒性反应。结果：12例中，7例达完全缓解，1例达部分缓解，总有效率为66.7%，持续缓解时间6～36个月。化疗相关毒性略大于HA和DA方案，主要特征为骨髓抑制期延长。结论：MAE方案可提高CD7+AML的缓解率，尽管化疗后骨髓抑制期延长，但能被患者耐受。“,”Objective:To study the effect of chemotherapy with MAE protocolfor CD7-positive acute myelogenous leukemia (CD7+AML) which represented a distinct biological and clinical subtype.Methods:Immunophenotyping in 97 patients of AML was tested by indirect immunofluorescence. Patients of CD7-positive expression received the treatment with MIT,Ara-c,Vp-16. The change of bone marrow and peripheral blood cell after chemotherapy and the clinical feature of related toxicity were monitored.Results:CD7+ was expressed in 12 patients (12.6%). Of the 12 patients, 7 cases achieved complete remission (CR), 1 case partial remission (PR), the overall response rate was approximately 66.7%, and DFS were 6～36 months. The chemotherapy related toxicity was slightly bigger than that of HA,DA protocol and the salient clinical features was the prolongation of the arrest interval of bone marrow.Conclusions:MAE protocol could improved CR rate in CD7+AML, bone marrow hemotopoietic impression was prolonged but no lethal complication existed.